Global Ion Channel Modulators Industry

Global Ion Channel Modulators Industry

  • April 2021 •
  • 165 pages •
  • Report ID: 1171462 •
  • Format: PDF
Abstract:
- Global Ion Channel Modulators Market to Reach $13.9 Billion by 2027
- Amid the COVID-19 crisis, the global market for Ion Channel Modulators estimated at US$11.1 Billion in the year 2020, is projected to reach a revised size of US$13.9 Billion by 2027, growing at aCAGR of 3.3% over the period 2020-2027. Channel Blockers, one of the segments analyzed in the report, is projected to record 3.6% CAGR and reach US$9.9 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Channel Openers segment is readjusted to a revised 2.6% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $3.3 Billion, While China is Forecast to Grow at 3.1% CAGR
- The Ion Channel Modulators market in the U.S. is estimated at US$3.3 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.5 Billion by the year 2027 trailing a CAGR of 3.1% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.1% and 2.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.

- Select Competitors (Total 39 Featured) -
  • Abcam plc
  • Ablynx NV
  • Airmid Inc.
  • Akashi Therapeutics
  • Inc.
  • Alion Pharmaceuticals Inc.
  • Allergan plc
  • AstraZeneca PLC
  • Aurora Biomed Inc.
  • Autifony Therapeutics Limited
  • Axxam S.p.A.
  • Bayer AG
  • Pharmaceuticals
  • Biogen
  • Inc.
  • Bio-Techne Corporation
  • CalciMedica
  • Inc.
  • Charles River Laboratories International Inc.